| Sep 16 |
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
|
| Sep 11 |
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
|
| Sep 5 |
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
|
| Sep 4 |
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
|
| Aug 28 |
Shuttle Pharma regains compliance with Nasdaq minimum bid price requirement
|
| Aug 28 |
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
| Aug 26 |
Shuttle pharma receives notice of Nasdaq non-compliance
|
| Aug 26 |
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
|
| Aug 14 |
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
|
| Jul 19 |
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
|
